Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | Ceritinib | ALK | RTK | 1.8283 | -0.4039 | 0.2184 | 0.0883 | 2.6153 | 2.323 | 0.99573 |
| Hs 578T | Cabozantinib | VEGFR2/MET | RTK | 6.3728 | 0.2155 | 0.1335 | 0.0452 | 1.3885 | 14.0588 | 0.89112 |
| HCC38 | Cediranib | VEGFR/cKIT | RTK | 1.5907 | -0.2044 | 0.2096 | 0.0416 | 1.0695 | 3.1564 | 0.98723 |
| HCC1806 | Ceritinib | ALK | RTK | 2.1149 | -0.4060 | 0.1766 | 0.0793 | 2.2387 | 2.8712 | 0.99364 |
| HCC1806 | Neratinib | EGFR/HER2 | RTK | 0.77903 | -0.0883 | 0.1927 | 0.0757 | 0.8116 | 3.0161 | 0.95894 |
| HCC1806 | Tivantinib | MET | RTK | 0.27161 | -0.2185 | 0.4464 | 0.1810 | 3.1555 | 0.30267 | 0.99849 |
| HCC1806 | Cediranib | VEGFR/cKIT | RTK | 4.9315 | 0.0954 | 0.0645 | 0.0363 | 4.9998 | 4.7786 | 0.98723 |
| HCC1806 | Cabozantinib | VEGFR2/MET | RTK | 11.367 | 0.6905 | -0.0025 | 0.0050 | 4.9955 | 13.3217 | 0.89668 |
| MCF7 | Ceritinib | ALK | RTK | 0.34376 | -0.6157 | 0.4566 | 0.1487 | 0.9502 | 0.88109 | 0.9932 |
| MCF7 | Cediranib | VEGFR/cKIT | RTK | 5.7041 | 0.1149 | 0.0758 | 0.0191 | 1.5383 | 11.6508 | 0.98993 |
| MCF7 | Cabozantinib | VEGFR2/MET | RTK | 4.8819 | -0.0993 | 0.1069 | 0.0302 | 1.8080 | 8.9638 | 0.99698 |
| MDA-MB-231 | Neratinib | EGFR/HER2 | RTK | 1.4329 | -0.0957 | 0.1056 | 0.0516 | 1.6284 | 2.8124 | 0.99527 |
| MDA-MB-231 | Tivantinib | MET | RTK | 0.41694 | -0.0845 | 0.3330 | 0.1029 | 2.2640 | 0.43275 | 0.99134 |
| Hs 578T | Ceritinib | ALK | RTK | 0.96543 | -0.4356 | 0.3052 | 0.1254 | 0.8330 | 3.6097 | 0.98175 |
| MCF 10A | Ceritinib | ALK | RTK | 2.9867 | -0.3186 | 0.1843 | 0.0521 | 1.3962 | 6.5603 | 0.98775 |
| SK-BR-3 | Tivantinib | MET | RTK | 0.27263 | -0.3523 | 0.4830 | 0.2060 | 2.4177 | 0.34098 | 0.99571 |
| SK-BR-3 | Cediranib | VEGFR/cKIT | RTK | 6.1955 | -0.5397 | 0.0755 | 0.0528 | 4.8242 | 7.7773 | 0.99548 |
| Hs 578T | Tivantinib | MET | RTK | 0.33668 | -0.3204 | 0.4411 | 0.2071 | 2.0560 | 0.42597 | 0.99878 |
| Hs 578T | Neratinib | EGFR/HER2 | RTK | 0.6444 | -0.1608 | 0.2025 | 0.0665 | 0.8744 | 2.2637 | 0.98743 |
| BT-20 | Tivantinib | MET | RTK | 0.47342 | -0.4883 | 0.4183 | 0.1893 | 2.5782 | 0.60346 | 0.99447 |
| Hs 578T | Cediranib | VEGFR/cKIT | RTK | 0.55083 | -0.5723 | 0.3937 | 0.1358 | 0.6641 | 2.8803 | 0.96002 |
| MCF 10A | Cediranib | VEGFR/cKIT | RTK | 9.6397 | 0.4781 | 0.0310 | 0.0012 | 3.3546 | 8.1 | 0.99825 |
| MCF 10A | Cabozantinib | VEGFR2/MET | RTK | 25.9104 | 0.8434 | -0.0114 | 0.0040 | 4.9998 | 11.7694 | 0.81226 |
| HCC70 | Cabozantinib | VEGFR2/MET | RTK | 1.5024 | -0.0911 | 0.2658 | 0.0226 | 0.5892 | 9.6961 | 0.92355 |
| HCC70 | Cediranib | VEGFR/cKIT | RTK | 4.5386 | -0.3262 | 0.0890 | 0.0440 | 2.2440 | 7.4053 | 0.99062 |